Skip to content

Geron GERN Change in AR

Change in AR at other companies

Incyte logo
IncyteINCY
$27.03M+187%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
-$120K-101%
Exelixis logo
ExelixisEXEL
$42.03M+161%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$6.5M+110%
Gilead Sciences logo
Gilead SciencesGILD
-$134M-69.6%
Biogen logo
BiogenBIIB
-$25.68M+53.8%

Other financials

Income statement

See full
Revenue$51.8M+30.9%
Operating income$158.0K+101%
Net income-$3.6M+81.6%
EPS (diluted)-$0.01+66.7%

Balance sheet

See full
Cash & equivalents$48.7M-12.2%
Total debt$134.0M+10.0%
Total equity$229.1M-14.6%
Total assets$534.1M-5.0%

Cash flow

See full
Operating cash flow-$62.9M-31.1%
CapEx$206.0K+2.0%
Free cash flow-$43.8M-6.8%

Valuation

See full
Market cap$878.88M-8.6%
Enterprise value$964.15M-6.2%
P/S4.7×-172×

Profitability

See full
Operating margin-705.5%-351pp
Net margin-682.5%-339pp
FCF margin-734.4%-365pp

Returns & leverage

See full
Return on equity-27.1%-7.8pp
Debt / equity0.6×+0.1×
Current ratio6.8×-1.1×

Where this comes from

Reported directly by Geron in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.

The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Geron's change in ar.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Geron's change in AR?
Geron (GERN) reported change in AR of $4.89M in Q1 2026.
How has Geron's change in AR changed year-over-year?
Geron's change in AR increased by 205.3% year-over-year, from -$4.65M to $4.89M.
What does change in AR mean?
Increase or decrease in amounts owed by customers — the primary working capital driver for many businesses.